CLINICAL TRIALS

Clinical trials are a fundamental step in the development of new therapies for treating virtually every medical condition. At Synta Pharmaceuticals, our clinical research is focused on innovative therapeutic options that can extend or enhance the lives of patients in the areas of cancer and inflammatory diseases. All of the drug candidates currently in development at Synta are derived from our proprietary chemical compound library and reflect our commitment to truly original research.

Synta places a high priority on sharing information and results regarding our ongoing and completed clinical studies with the medical community.

Phase 3 Clinical Trial in Metastatic Melanoma

Elesclomol in Metastatic Melanoma

In September 2007, Synta Pharmaceuticals initiated the Phase 3 SYMMETRY^SM clinical trial of elesclomol (formerly STA-4783). The SYMMETRY trial will enroll approximately 630 patients with stage IV metastatic melanoma. Synta anticipates the SYMMETRY trial will enroll patients at approximately 150 centers in 15 countries across North and South America, Europe and Australia. For more information on the SYMMETRY trial or to find the clinical trial center in your region, please see:

• www.centerwatch.com/SYMMETRY;
• www.clinicaltrials.gov, study number NCT00522834; or
• www.symmetrymelanomastudy.com.